Formulation and Evaluation of Famotidine Floating Matrix Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Formulation and Evaluation of Famotidine Floating Matrix Tablets
The authors investigated the effects of formulation and processing parameters on floating matrix-controlled drug-delivery systems.


Pharmaceutical Technology
Volume 33, Issue 10, pp. 60-70

Results and discussion

Floating behavior. Incorporating the highly porous powder in the matrix tablets results in densities that are lower than the density of the release medium (compared with 1.00 g/cm for the release the medium). Approximately 12% w/w of low-density copolymer powder (based on the mass of the tablet) was sufficient to achieve proper in vitro floating behavior for at least 8 h. In contrast to most conventional floating systems (including gas-generating systems), these tablets floated immediately upon contact with the release medium and thus showed no lag times in floating (time = 0). Extended floating times were achieved as a result of the air entrapped within the low-density powder particles, which is only slowly removed from the system upon contact with the release medium. As expected, tablets without poly(styrene–divinyl benzene) copolymer powder (e.g., consisting of 40 mg of polymer and 40 mg of famotidine) sank to the bottom of the vessel showing no floating behavior.Adding 15% w/w (based on the mass of the tablet) of low-density powder reduced the lag times to 0 s.


Figure 1: Effect of various matrix-forming polymers on drug release using USP paddle method.
In vitro drug release. To evaluate the hydrophilic matrixing polymers used to prepare floating matrix tablets; seven polymers (sodium alginate, Xanthan 150, Klucel HXF, chitosan, psyllium, HPMC K15 M, and HPMC K100 M) were selected and dosage forms were prepared and evaluated for individual drug-release profiles. Approximately 12.6 % of low-density powder was added to these formulations initially. Results showed that the type of polymer influenced the drug-release pattern (see Figure 1).

A significantly lower rate and extent of drug release was observed from the batches B2, B3, and B6 compared with batches B1 and B7. Formulations made with chitosan (batch B4) and psyllium (batch B5) eroded at the end of 6 h, releasing 98.96 % and 99.98 % of drug, respectively. These polymers were therefore unsuitable for the desired floating matrix tablets of famotidine. The integrity of tablets made with chitosan was much better than that of tablets prepared with psyllium. The initial burst effects for the formulations B2, B3, and B6 were much lower than the required theoretical value, while those for formulations B1 and B7 (containing sodium alginate and HPMC K15 M) were near to the required theoretical profile value (which was calculated using the equations of immediate-release dose and maintenance dose). The floating lag time for most of the batches was within 5 s. Thus the low density powder poly(styrene-divinyl benzene) copolymer (PSDVB) showed its role in the buoyancy of the formulations.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here